Aeon Biopharma IncNYSE American:AEON
- LAST PRICE0.5610
- TODAY'S CHANGE (%)0.0020 (0.3578%)
- Bid / Lots0.5522/ 1
- Ask / Lots0.5610/ 2
- Open / Previous Close0.5590 / 0.5590
- Day Range
- 52 Week Range
- Volume95,467
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AEON |
|---|---|---|
| 09:32 ET | 572 | 0.5545 |
| 09:35 ET | 10480 | 0.5289 |
| 09:37 ET | 490 | 0.5206 |
| 09:39 ET | 7292 | 0.5206 |
| 09:50 ET | 200 | 0.557 |
| 09:51 ET | 5100 | 0.53 |
| 09:55 ET | 100 | 0.557 |
| 09:57 ET | 200 | 0.5572 |
| 10:04 ET | 1500 | 0.554354 |
| 10:08 ET | 2666 | 0.5525 |
| 10:09 ET | 2843 | 0.5559 |
| 10:11 ET | 300 | 0.559 |
| 10:13 ET | 700 | 0.55556 |
| 10:15 ET | 12324 | 0.5572 |
| 10:20 ET | 500 | 0.5794 |
| 10:24 ET | 1000 | 0.5667 |
| 10:26 ET | 819 | 0.5552 |
| 10:27 ET | 300 | 0.579 |
| 10:33 ET | 1000 | 0.5667 |
| 10:38 ET | 100 | 0.579 |
| 10:42 ET | 3284 | 0.5667 |
| 10:47 ET | 300 | 0.5544 |
| 10:56 ET | 200 | 0.57 |
| 11:00 ET | 300 | 0.5544 |
| 11:02 ET | 523 | 0.5544 |
| 11:05 ET | 100 | 0.57 |
| 11:07 ET | 7104 | 0.5622 |
| 11:14 ET | 300 | 0.57 |
| 11:18 ET | 200 | 0.57 |
| 11:21 ET | 1000 | 0.5681 |
| 11:23 ET | 2700 | 0.5544 |
| 11:25 ET | 511 | 0.55 |
| 11:30 ET | 160 | 0.56 |
| 11:32 ET | 100 | 0.56 |
| 11:59 ET | 100 | 0.567 |
| 12:12 ET | 100 | 0.567 |
| 12:15 ET | 100 | 0.567 |
| 12:17 ET | 100 | 0.5548 |
| 12:24 ET | 600 | 0.5541 |
| 12:30 ET | 200 | 0.56 |
| 12:35 ET | 100 | 0.5652 |
| 12:42 ET | 182 | 0.5596 |
| 12:48 ET | 100 | 0.5652 |
| 12:51 ET | 5900 | 0.5535 |
| 12:57 ET | 800 | 0.5525 |
| 01:08 ET | 1600 | 0.552 |
| 01:15 ET | 111 | 0.561 |
| 01:18 ET | 100 | 0.561 |
| 01:27 ET | 100 | 0.5566 |
| 01:36 ET | 1271 | 0.5564 |
| 01:40 ET | 100 | 0.561 |
Nov 13, 2024
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow JonesPress Release: AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aeon Biopharma Inc | 22.1M | -0.1x | --- |
Cocrystal Pharma Inc | 21.9M | -1.2x | --- |
Cell Source Inc | 22.3M | -3.5x | --- |
X T L Biopharmaceuticals Ltd | 21.8M | -5.2x | --- |
Tempest Therapeutics Inc | 22.5M | -0.6x | --- |
Forte Biosciences Inc | 22.8M | -0.8x | --- |
Company Information
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.
Contact Information
- Headquarters
- 5 Park Plaza, Suite 1750IRVINE, CA, United States 92614
- Phone
- 949-354-6499
- Fax
- 302-655-5049
Executives
- Chairman Nominee of the Board
- Jost Fischer
- President, Chief Executive Officer, Principal Financial Officer, Director
- Marc Forth
- Executive Vice President, Chief Legal Officer, Corporate Secretary
- Alex Wilson
- Principal Accounting Officer
- Jennifer Sy
- Chief Medical Officer
- Chad Oh
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.5M |
Aeon Biopharma Inc does not pay a dividend. | |
Beta | 0.26 |
EPS | $-9.61 |
Book Value | $-4.12 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
